why did the united states change to digital- Top People also ask

CITIC Securities: The supply and demand pattern may meet the turning point, paying attention to the strategic allocation value of the magnesium industry. CITIC Securities Research Report said that magnesium prices have stopped falling and stabilized recently, and magnesium as a strategic attribute of China's superior resources is expected to continue to improve. At present, there is a widespread cost inversion in factories, and the willingness to support the price by cost is enhanced, and the purchasing and storage measures are superimposed. We believe that the magnesium price is expected to open an upward channel. At present, the ratio of magnesium to aluminum is reduced to about 0.9 at the bottom, which is conducive to the accelerated promotion of magnesium alloys, and the downstream fields such as new energy vehicles, low-altitude economy, humanoid robots and solid hydrogen storage have broad prospects.Luckin Coffee will open seven stores in Mong Kok, Tsim Sha Tsui and Sheung Wan. (Sing Tao Daily)CITIC Securities: More positive policy signals are expected to drive the market of resource products. CITIC Securities Research Report said that the Politburo meeting released more positive policy signals, and the improvement of the real economy is expected to boost the prices of upstream resource products and lead the sector to return to the upward trend. It is suggested to focus on three main lines: 1) improving the fundamentals of general steel, coking coal, copper-aluminum basic metals and chemicals with strong consumption attributes; 2) Bonus varieties such as crude oil and thermal coal under favorable market liquidity; 3) Growing varieties such as lithium and rare earth under the favorable market style.

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Byte internal judges that the ceiling of AI dialogue products may not be high, so it is necessary to improve the priority of cutting and dreaming. It is learned from informed sources that Byte management judges that AI dialogue products (or chatbot products) may only be the "intermediate state" of AI products, and a more ideal product form for a long time requires a more visual user experience and a lower threshold for users to use. Therefore, Byte has promoted the product priority of Dreaming, and tried to create a "Tik Tok" in the AI ​ ​ era with a new path. In this regard, I asked the byte for verification, and the byte did not respond. (36Kr)Argentine President Millai: Argentines can now trade in any currency.

Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.During the year, there were 461 new indices, and the index investment fever continued to climb. On December 10th, in order to meet the investment demand of diversified indices, CSI Index Co., Ltd. officially released five new indices, including CSI 1000 Growth Index, CSI 1000 Value Index, CSI 2000 Growth Index, CSI 2000 Value Index and CSI 1000 Quality Balance Strategy Index. With the "listing" of the above five indexes, the number of newly-issued indexes reached 461 during the year, covering categories such as strategy, style, scale, industry, theme and other fixed-income indexes; Related index asset classes include stocks, fixed income, funds and futures. At the same time, the secondary market, this year, the heat of indexed investment is also high. Looking forward to the future, with the continuous vigorous growth of market demand and unabated heat, and the precise guidance and strong support from the supervisory level, the indexed investment ecology will become more and more perfect. (Securities Daily)On December 10th, 36 stocks hit record highs mainly in transportation equipment, mechanical equipment and other industries. According to statistics, on December 10th, a total of 36 stocks hit record highs, mainly in transportation equipment, mechanical equipment and other industries, including Cyrus, Tuosida, Keli Sensing, Straight Flush, Focus Technology and so on.